RCM
DYN icon

RA Capital Management’s Dyne Therapeutics DYN Stock Holding History

RA Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,714,392
Closed -$92.5M – 69
2025
Q2 		$92.5M Hold
9,714,392
– – 1.56% 17
2025
Q1 		$102M Buy
9,714,392
+3,333,248
+52% +$47.7M 1.7% 14
2024
Q4 		$150M Hold
6,381,144
– – 2% 12
2024
Q3 		$229M Buy
6,381,144
+331,940
+5% +$13.2M 2.64% 11
2024
Q2 		$213M Buy
6,049,204
+1,094,425
+22% +$31.8M 2.82% 10
2024
Q1 		$141M Buy
+4,954,779
New +$112M 1.79% 17
2022
Q3 		– Sell
-2,805,045
Closed -$19.3M – 86
2022
Q2 		$19.3M Hold
2,805,045
– – 0.51% 47
2022
Q1 		$27M Hold
2,805,045
– – 0.59% 49
2021
Q4 		$33.4M Hold
2,805,045
– – 0.59% 51
2021
Q3 		$45.6M Hold
2,805,045
– – 0.63% 41
2021
Q2 		$59M Hold
2,805,045
– – 0.95% 30
2021
Q1 		$43.6M Hold
2,805,045
– – 0.66% 43
2020
Q4 		$58.9M Hold
2,805,045
– – 0.82% 37
2020
Q3 		$56.6M Buy
+2,805,045
New +$61.6M 1.04% 30

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RA Capital Management's DYN Position: Q3 2025 in Review

RA Capital Management sold out of Dyne Therapeutics (DYN) in Q3 2025, closing a stake of 9,714,392 shares — an estimated $92.5M sold.

RA Capital Management first reported a position in DYN in Q3 2020 and held it in 14 quarters. The position peaked at $229M in Q3 2024. 207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

  • RA Capital Management reported no remaining Dyne Therapeutics position as of Q3 2025 after selling out during the quarter.
  • RA Capital Management sold 9,714,392 Dyne Therapeutics shares in Q3 2025, an estimated $92.5M.
  • RA Capital Management first reported a position in Dyne Therapeutics in Q3 2020 and held it in 14 quarters.
  • RA Capital Management's Dyne Therapeutics position peaked at $229M in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on RA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.